AKT1 and Miyoshi myopathy: Since clinical trials involving PI3K [59] or AKT [60] inhibition, alone or in combination with conventional mutBRAF or MEK targeting drugs have shown poor benefit for MM patients, direct ferroptosis induction may provide a promising alternative.